Johnson & Johnson Kick Starts 2018 with 15 New Deals
Johnson & Johnson decided to kick start the new year by striking 15 new collaborations to drive the development of novel solutions to impact healthcare. These collaborations bring the total number of strategic transactions executed by Johnson & Johnson Innovation to more than 350 since its establishment in 2012.
This latest series of deals focuses on leveraging advances in science and technology to address areas of high unmet medical need, including the use of artificial intelligence to detect signs of Alzheimer’s disease years before it becomes apparent; the identification of throat cancers with a simple saliva test; and harnessing the microbiome to treat sleep disorders.
“Our highest priority is to improve the health of people around the globe, and each collaboration announced today represents a unique opportunity to explore novel therapeutics, medical devices and consumer health solutions,” said Paul Stoffels, M.D., Executive Vice President and Chief Scientific Officer, Johnson & Johnson. “By advancing transformative healthcare innovations together with entrepreneurs, academic centers and institutions, we are one step closer to addressing many pressing global healthcare challenges.”
The collaborations include:
1. Fighting Alzheimer’s Disease with Gene Therapy
Johnson & Johnson and Janssen Pharmaceuticals have established an exclusive research collaboration with the University of Pennsylvania’s Gene Therapy Program that will utilize Adeno-associated virus (AAV)-vectors developed by the University of Pennsylvania and antibodies targeting Alzheimer’s disease developed by JPI. The collaboration aims to use AAV viral delivery to express therapeutic antibodies that target the main pathological hallmarks of Alzheimer’s disease.
2. Measuring Neuropsychological Health
Johnson & Johnson and Janssen Pharmaceuticals announced a collaboration with the Northern California Institute for Research and Education and the San Francisco Veterans Affairs Medical Center to investigate the utility of online neuropsychological assessments to monitor brain health in elderly people.
3. Exploring the Role of the Microbiome in Sleep
Johnson & Johnson and Janssen Research & Development have established an exclusive research collaboration with Holobiome Corporation, a developer of microbiome therapeutics, to treat diseases of the central and enteric nervous systems. The collaboration will examine a consortium of bacteria that could be used to create a differentiated probiotic or over-the-counter offering that addresses sleeplessness.
4. Leveraging AI to Predict Neurodegenerative Diseases
Johnson & Johnson facilitated an exclusive feasibility study between Janssen Research & Development and WinterLight Labs. The research will evaluate WinterLight’s proprietary technology for analyzing voice samples obtained from Janssen Research & Development’s ongoing clinical trials in Alzheimer’s and neurodegenerative diseases. The goal is to non-invasively predict dementia and neurodegenerative diseases long before clinical symptoms become apparent.
5. Preventing, Intercepting and Curing Lung Cancer
The Johnson & Johnson Lung Cancer Initiative (LCI) announced a collaboration with the Koch Institute for Integrative Cancer Research at MIT to conduct research aimed at eradicating lung cancer.
6. Developing a Saliva Test for Cancer
Johnson & Johnson and Janssen Cilag Pty Ltd. have extended a collaboration with Queensland University of Technology to develop a saliva-based diagnostic for early detection of throat cancers.
7. Advancing Biomarker Diagnostics for Lung Cancer
To advance ground-breaking science and health solutions for lung cancer, Johnson & Johnson and Janssen Pharmaceutica NV have formed a collaboration with MiRXES Pte Ltd, to develop a novel lung cancer diagnostic test with the aim to improve the detection of early-stage disease.
8. Harnessing Bacteria to Fight Skin Disease
Johnson & Johnson have formed a collaboration with JLABS, Dermala Inc. to develop microbiome-derived treatments for skin conditions.
9. Preventing Psoriasis
Johnson & Johnson and Janssen Biotech Inc. have extended a research collaboration with Monash University aimed at further exploring the underlying triggers of psoriasis to discover and develop potential new treatments that prevent future occurrences of the disease.
10. Improving Skin Biopsies
Johnson & Johnson and Janssen Biotech Inc. have formed a collaboration with MiNDERA, a JLABS @ South San Francisco resident company. MiNDERA is advancing a minimally invasive microneedle device to better enable the research, diagnosis and treatment of inflammatory skin diseases at the molecular level.
11. Discovering Novel Therapeutics for Obesity
Janssen Pharmaceuticals, Inc. has formed a multi-year research collaboration with Beacon Discovery Inc., a G-Protein Coupled Receptor (GCPR) drug discovery incubator, to discover and develop next-generation therapeutics to treat obesity and other metabolic diseases.
12. Driving Innovation Through Partnering
Johnson & Johnson is collaborating with Monash University, supported by the State Government of Victoria, to establish the Johnson & Johnson Innovation Partnering Office @ Monash (JJIPO @ Monash). The partnering office will work with Victoria’s medtech and pharma ecosystem to source Victorian technologies and deliver training, mentoring and networking programs to the next generation of entrepreneurs for the benefit of patients globally.
13. Seeing the Future of Vision Care Up Close
Johnson & Johnson have extended their long-standing collaboration with Queensland University of Technology to research and develop novel contact lenses to slow the progression of myopia and bring breakthrough eye health solutions to people around the world.
14. Discovering Objective Biomarkers for Ocular Response to Contact Lens Wear
Johnson & Johnson has formed a collaboration with Narayana Nethralaya Foundation and Medical Research Foundation for the discovery and validation phases of developing diagnostic tools that can be used to identify a person’s unique vision-care needs to help facilitate the matching of vision correction options.
15. Advancing Life Science Research and Development Activities in Taiwan
Johnson & Johnson, Asia Pacific and Janssen Research & Development, have formed a collaboration with the Taiwan Industrial Technology Research Institute to set up co-funding agreements for projects in lung cancer, chronic obstructive pulmonary disease, diabetes, eye health and digital health initiatives.